New Jersey Headlines

Delveinsight Business Research LLP

“Eosinophilic Esophagitis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Eosinophilic Esophagitis Market. 

The Eosinophilic Esophagitis Pipeline report embraces in-depth commercial, regulatory, and Eosinophilic Esophagitis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Eosinophilic Esophagitis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Eosinophilic Esophagitis Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for Eosinophilic Esophagitis treatment and the aggregate therapies developed by major pharma companies.

• It accesses the different Eosinophilic Esophagitis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the major Eosinophilic Esophagitis companies involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the Eosinophilic Esophagitis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Eosinophilic Esophagitis therapeutic market.

Eosinophilic Esophagitis Therapeutics Landscape

Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus. It is characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation of the esophagus. It is currently the second most common cause of chronic esophagitis after gastro-esophageal reflux disease (GORD) and the main cause of dysphagia and food impaction in children and young adults. Although it is not associated with mortality or risks of malignancy, its chronic nature, and progressive behavior adversely impact patients’ quality of life.

Current EoE treatment includes the use of drugs or dietary modifications capable of inducing and maintaining remission of symptoms and esophageal eosinophilia infiltration and endoscopic dilation to resolve strictures or reduced caliber of the esophagus, as a consequence of the fibrotic remodeling process of the esophagus.

There are approx. 18+ key companies developing therapies for Eosinophilic Esophagitis. At present, Takeda, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Ellodi Pharmaceuticals, AstraZeneca, Allakos, EsoCap AG, Arena Pharmaceutical, GlaxoSmithKline and others are actively working to overcome the unmet medical needs of the currently used therapeutics. Currently, Ellodi Pharmaceuticals is leading the therapeutics market with its Eosinophilic Esophagitis drug candidates in the most advanced stage of clinical development.

Eosinophilic Esophagitis Companies Actively Working in the Therapeutic Market Include:

Allakos, Aqilion, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb (BMS), Calypso Biotech, DBV Technologies, Dr Falk Pharma, Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline, Kyowa Hakko Kirin, Landos Biopharma, Pfizer, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Sanofi, Serpin Pharma, Takeda, and many others.

Emerging and Marketed Eosinophilic Esophagitis Drugs Covered in the Report Include:

• APT-1011: Ellodi Pharmaceuticals.

• Benralizumab: AstraZeneca

• Budesonide Oral Suspension: Takeda

• Cendakimab: Bristol-Myers Squibb

• Dupilumab: Regeneron Pharmaceuticals/Sanofi

• ESO-101: EsoCap AG

• Etrasimod: Arena Pharmaceutical

• Lirentelimab: Allakos

• Mepolizumab: GlaxoSmithKline

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Eosinophilic Esophagitis Companies Working in the Market @ 

https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight

Analysis of Emerging Eosinophilic Esophagitis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued and inactive candidates

Route of Administration

Eosinophilic Esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

• Peptide

• Protein

• Propylene glycols

• Cell Therapy

Learn How the Eosinophilic Esophagitis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Eosinophilic Esophagitis Treatment Patterns

4. Eosinophilic Esophagitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Eosinophilic Esophagitis Late Stage Products (Phase-III)

7. Eosinophilic Esophagitis Mid-Stage Products (Phase-II)

8. Eosinophilic Esophagitis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Eosinophilic Esophagitis Discontinued Products

13. Eosinophilic Esophagitis Product Profiles

14. Major Eosinophilic Esophagitis Companies in the Market

15. Key Products in the Eosinophilic Esophagitis Therapeutics Segment

16. Dormant and Discontinued Products

17. Eosinophilic Esophagitis Unmet Needs

18. Eosinophilic Esophagitis Future Perspectives

19. Eosinophilic Esophagitis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Varicose Ulcer Market

“Varicose Ulcer Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Varicose Ulcer market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Varicose Ulcer market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology